BCR/ABL t(9;22) by FISH : 1003132

Please provide most recent Pathology report.

MDFCPBCRABLFG or 1003132

9;22 translocation, FISH; Abelson Oncogene; Acute Lymphoblastic Leukemia; BCR Major and Minor Breakpoints; BCR-ABL, FISH; Breakpoints Cluster Region; Fluorescent In Situ Hybridization with BCR/ABL; Chronic Myeloid Leukemia; CML and ALL, BCR/ABL, FISH; FISH (Fluorescent In Situ Hybridization); FISH, BCR/ABL Fusion; Fluorescence In Situ Hybridization (FISH) with BCR/ABL; Fluorescence In Situ Hybridization DNA Probes (D-FISH)with BCR/ABL; Fluorescent In Situ Hybridization (FISH); Ph chromosome; Philadelphia Chromosome Ph1 Bone Marrow/Blood; t(9:22), FISH

Bone Marrow aspirate in a green top sodium heparin tube (2-3 mL) or Peripheral Blood in a green top sodium heparin tube (2-10 mL). Tissue also accepted.

Blood or Bone Marrow: Do not centrifuge. Paraffin embedded formalin fixed tissue that has been fixed in 10% neutral buffered formalin for at least 6 hours and no longer than 48 hours. Two unstained slides, with tissue of 4 microns in thickness are needed for processing, accompanied by a circled H & E clearly indicating the area to be examined.

Blood or Bone Marrow: Ambient temperature within 24 hours. Specimen can be refrigerated if not transported immediately. Do not freeze. Protect from heat with a cold pack. Paraffin embedded tissue block: Ambient or on ice pack in summer. Slides: Ambient.

Blood and Bone Marrow: Ambient: 48 hours; Refrigerated: 48 hours; Frozen: Unacceptable

Paraffin embedded tissue: Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable

Monday - Friday

Up to 7 days

Laboratory test results should always be considered in the context of clinical observations. This test was developed and its performance characteristics determined by med fusion. It has not been cleared or approved by the U.S. Food and Drug Administration
(FDA). The FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes. It should not be regarded as investigational for research. This laboratory is certified under the Clinical Laboratory Improvement Amendments
of 1988 (CLIA) as qualified to perform high complexity clinical laboratory testing.

An interpretive report will be provided.

The BCR/ABL translocation is found in virtually all cases of chronic myelogenous leukemia (CML) and in a subset of acute lymphoblastic leukemia (ALL). These cases are characterized by an aberrant gene rearrangement between the abl protooncogene on chromosome 9 and the breakpoint cluster region (BCR) on chromosome 22. The bcr/abl rearrangement may be detected even when no Philadelphia chromosome is observed by conventional cytogenetics. The detection of t(9;22) is supportive of a clinical diagnosis of chronic myelogenous leukemia (CML). Detection of t(9;22) is also useful in the distinction of reactive causes of persistent leukocytosis from CML, the distinction of CML from other chronic myeloproliferative disorders (e.g. polycythemia vera, essential thrombocythemia, and agnogenic myeloid metaplasia), and the distinction of CML from chronic myelomono-cytic leukemia. Due to the high correlation between the bcr/abl major translocation and CML, detection and quantification of bcr/abl transcripts is useful in monitoring minimal residual disease and genetic recurrence after treatment. A subset of acute lymphoblastic leukemias harbors the t(9;22). The identification of the t(9;22) has adverse prognostic implications in ALL.